157 related articles for article (PubMed ID: 36087523)
1. Generation of heterozygous SAMD9 CRISPR/Cas9-edited iPSC line (ESi086-A-3), carrying p.I1567M mutation.
Pera J; Castaño J; Casamitjana J; Giorgetti A; Romero-Moya D
Stem Cell Res; 2022 Oct; 64():102906. PubMed ID: 36087523
[TBL] [Abstract][Full Text] [Related]
2. Generation of two heterozygous GATA2 CRISPR/Cas9-edited iPSC lines, R398W and R396Q, for modeling GATA2 deficiency.
Castaño J; Romero-Moya D; Richaud-Patin Y; Giorgetti A
Stem Cell Res; 2021 Aug; 55():102445. PubMed ID: 34284273
[TBL] [Abstract][Full Text] [Related]
3. Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9/SAMD9L syndromes.
Sahoo SS; Pastor VB; Goodings C; Voss RK; Kozyra EJ; Szvetnik A; Noellke P; Dworzak M; Starý J; Locatelli F; Masetti R; Schmugge M; De Moerloose B; Catala A; Kállay K; Turkiewicz D; Hasle H; Buechner J; Jahnukainen K; Ussowicz M; Polychronopoulou S; Smith OP; Fabri O; Barzilai S; de Haas V; Baumann I; Schwarz-Furlan S; ; Niewisch MR; Sauer MG; Burkhardt B; Lang P; Bader P; Beier R; Müller I; Albert MH; Meisel R; Schulz A; Cario G; Panda PK; Wehrle J; Hirabayashi S; Derecka M; Durruthy-Durruthy R; Göhring G; Yoshimi-Noellke A; Ku M; Lebrecht D; Erlacher M; Flotho C; Strahm B; Niemeyer CM; Wlodarski MW
Nat Med; 2021 Oct; 27(10):1806-1817. PubMed ID: 34621053
[TBL] [Abstract][Full Text] [Related]
4. In trans early mosaic mutational escape and novel phenotypic features of germline SAMD9 mutation.
Hockings C; Gohil S; Dowse R; Hoade Y; Mansour MR; Gale RE; Linch DC; Rao A; Payne EM
Br J Haematol; 2020 Feb; 188(4):e53-e57. PubMed ID: 31900929
[No Abstract] [Full Text] [Related]
5. Pediatric MDS and bone marrow failure-associated germline mutations in SAMD9 and SAMD9L impair multiple pathways in primary hematopoietic cells.
Thomas ME; Abdelhamed S; Hiltenbrand R; Schwartz JR; Sakurada SM; Walsh M; Song G; Ma J; Pruett-Miller SM; Klco JM
Leukemia; 2021 Nov; 35(11):3232-3244. PubMed ID: 33731850
[TBL] [Abstract][Full Text] [Related]
6. [Predisposition and progression of myelodysplastic syndromes].
Makishima H
Rinsho Ketsueki; 2021; 62(4):278-288. PubMed ID: 33967153
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of Hematopoietic Cell Transplantation in Patients with Germline SAMD9/SAMD9L Mutations.
Ahmed IA; Farooqi MS; Vander Lugt MT; Boklan J; Rose M; Friehling ED; Triplett B; Lieuw K; Saldana BD; Smith CM; Schwartz JR; Goyal RK
Biol Blood Marrow Transplant; 2019 Nov; 25(11):2186-2196. PubMed ID: 31306780
[TBL] [Abstract][Full Text] [Related]
8. A familial
Rahim MQ; Rahrig A; Overholt K; Conboy E; Czader M; Saraf AJ
Cold Spring Harb Mol Case Stud; 2023 Apr; 9(2):. PubMed ID: 37160314
[TBL] [Abstract][Full Text] [Related]
9. Determining the Pathogenicity of a Genomic Variant of Uncertain Significance Using CRISPR/Cas9 and Human-Induced Pluripotent Stem Cells.
Ma N; Zhang JZ; Itzhaki I; Zhang SL; Chen H; Haddad F; Kitani T; Wilson KD; Tian L; Shrestha R; Wu H; Lam CK; Sayed N; Wu JC
Circulation; 2018 Dec; 138(23):2666-2681. PubMed ID: 29914921
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of germline GATA2 and SAMD9/9L variants in paediatric haematological disorders with monosomy 7.
Yoshida M; Tanase-Nakao K; Shima H; Shirai R; Yoshida K; Osumi T; Deguchi T; Mori M; Arakawa Y; Takagi M; Miyamura T; Sakaguchi K; Toyoda H; Ishida H; Sakata N; Imamura T; Kawahara Y; Morimoto A; Koike T; Yagasaki H; Ito S; Tomizawa D; Kiyokawa N; Narumi S; Kato M
Br J Haematol; 2020 Dec; 191(5):835-843. PubMed ID: 32770553
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the application of induced pluripotent stem cell technology to the study of myeloid malignancies.
Tatwavedi D; Pellagatti A; Boultwood J
Adv Biol Regul; 2024 Jan; 91():100993. PubMed ID: 37827894
[TBL] [Abstract][Full Text] [Related]
12. Evolution of histomorphologic, cytogenetic, and genetic abnormalities in an untreated patient with MIRAGE syndrome.
Rentas S; Pillai V; Wertheim GB; Akgumus GT; Nichols KE; Deardorff MA; Conlin LK; Li MM; Olson TS; Luo M
Cancer Genet; 2020 Jul; 245():42-48. PubMed ID: 32619790
[TBL] [Abstract][Full Text] [Related]
13. FBXO11 is a candidate tumor suppressor in the leukemic transformation of myelodysplastic syndrome.
Schieber M; Marinaccio C; Bolanos LC; Haffey WD; Greis KD; Starczynowski DT; Crispino JD
Blood Cancer J; 2020 Oct; 10(10):98. PubMed ID: 33024076
[TBL] [Abstract][Full Text] [Related]
14. Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes.
Wong JC; Bryant V; Lamprecht T; Ma J; Walsh M; Schwartz J; Del Pilar Alzamora M; Mullighan CG; Loh ML; Ribeiro R; Downing JR; Carroll WL; Davis J; Gold S; Rogers PC; Israels S; Yanofsky R; Shannon K; Klco JM
JCI Insight; 2018 Jul; 3(14):. PubMed ID: 30046003
[TBL] [Abstract][Full Text] [Related]
15. Stage-Specific Human Induced Pluripotent Stem Cells Map the Progression of Myeloid Transformation to Transplantable Leukemia.
Kotini AG; Chang CJ; Chow A; Yuan H; Ho TC; Wang T; Vora S; Solovyov A; Husser C; Olszewska M; Teruya-Feldstein J; Perumal D; Klimek VM; Spyridonidis A; Rampal RK; Silverman L; Reddy EP; Papaemmanuil E; Parekh S; Greenbaum BD; Leslie CS; Kharas MG; Papapetrou EP
Cell Stem Cell; 2017 Mar; 20(3):315-328.e7. PubMed ID: 28215825
[TBL] [Abstract][Full Text] [Related]
16. Revertant somatic mosaicism as a cause of cancer.
Inaba T; Nagamachi A
Cancer Sci; 2021 Apr; 112(4):1383-1389. PubMed ID: 33583097
[TBL] [Abstract][Full Text] [Related]
17. [Novel germline SAMD9 mutation in an elderly patient with myelodysplastic syndrome].
Uchida T; Fujii T; Ohara S; Imai Y; Inoue M; Harada Y; Harada H; Hagihara M
Rinsho Ketsueki; 2022; 63(8):865-869. PubMed ID: 36058856
[TBL] [Abstract][Full Text] [Related]
18. SAMD9 and SAMD9L in inherited predisposition to ataxia, pancytopenia, and myeloid malignancies.
Davidsson J; Puschmann A; Tedgård U; Bryder D; Nilsson L; Cammenga J
Leukemia; 2018 May; 32(5):1106-1115. PubMed ID: 29535429
[TBL] [Abstract][Full Text] [Related]
19. Generation of CRISPR/Cas9 edited human induced pluripotent stem cell line carrying the heterozygous p.H695VfsX5 frameshift mutation in the exon 10 of the PKP2 gene.
Pierre B; Laëtitia DB; Camille B; Claire P; Elise B; Estelle G; Vincent F; Eric V
Stem Cell Res; 2024 Apr; 76():103341. PubMed ID: 38382214
[TBL] [Abstract][Full Text] [Related]
20. Generation of CRISPR-Cas9 edited human induced pluripotent stem cell line carrying BAG3 V468M mutation in its BAG domain.
Duboscq-Bidot L; Hoareau B; Ader F; Fontaine V; Villard E
Stem Cell Res; 2024 Feb; 74():103294. PubMed ID: 38183888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
